38% reduction in the risk of progression (p < 0.001) in the Atezolizumab combination arm.This benefit was observed regardless of EGFR/ALK statusThese results led to the approval of the combination in the first-line treatment of NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.